KKU-M213 CDX Model

The KKU-M213 cell line is derived from human intrahepatic cholangiocarcinoma (ICC), a rare and aggressive malignancy originating from the bile ducts within the liver. ICC is characterized by its insidious onset and challenging therapeutic management. KKU-M213 provides an indispensable platform for delving into ICC’s complex biology, understanding its pathogenesis, and assessing therapeutic avenues. This cell line embodies the molecular signatures and genetic abnormalities typical of ICC, accentuating its value in preclinical research. The in vitro and in vivo behavior of KKU-M213 sheds light on ICC’s growth kinetics, invasive properties, and potential metastatic tendencies. Researchers utilize the KKU-M213 model to decipher molecular pathways pivotal to ICC progression, to test drug responses, and to pioneer therapeutic strategies targeting ICC’s unique molecular vulnerabilities.

Model Details

Cancer Location: Liver
Cancer Type: Intrahepatic Cholangiocarcinoma
Model Name: KKU-M213
Mouse Strain: NSG
Treatment Data Available: Chemotherapy (Gemcitabine, Cisplatin)

KKU-M213 Growth subcurves

KKU-M213 CDX Model

Growth of subcutaneous KKU-M213 in Nu/Nu mice (n=10 mice)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.